title: Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction.
abstract: We prospectively followed 202 patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40%). Patients were divided into 2 groups: groups I (simvastatin group, n = 106, aged 60.8 +/- 10.3 years, men 71.7%) and II (non-simvastatin group, n = 96, aged 60.9 +/- 10.4 years, men 78.1%). During 1-year clinical follow-up, simvastatin therapy was associated with a significant reduction in mortality (1.9% vs 7.5%, p = 0.048), restenosis rate (25.7% vs 43.1%, p = 0.033), and repeat PCI rate (25.7% vs 43.1%, p = 0.033), and with significant improvement in LV ejection fraction (31% to 42% vs 32% to 39%, p = 0.042). The event-free survival rate was higher in group I than in group II (79.8% vs 57.0%, p = 0.001). In conclusion, simvastatin therapy improves LV systolic function and decreases mortality, restenosis, and repeat PCI rate in patients with ischemic heart failure who underwent PCI for acute myocardial infarction.
authors.affiliation: The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Science, Gwangju, Korea.
authors.forename: Young Joon
authors.initials: YJ
authors.lastname: Hong
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Dae Woo
authors.initials: DW
authors.lastname: Hyun
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Kwon Bae
authors.initials: KB
authors.lastname: Kim
authors.forename: Weon
authors.initials: W
authors.lastname: Kim
authors.forename: Sang Yup
authors.initials: SY
authors.lastname: Lim
authors.forename: Sang Hyun
authors.initials: SH
authors.lastname: Lee
authors.forename: Seo Na
authors.initials: SN
authors.lastname: Hong
authors.forename: Dong Goo
authors.initials: DG
authors.lastname: Kang
authors.forename: Kyung Ho
authors.initials: KH
authors.lastname: Yun
authors.forename: Kye Hun
authors.initials: KH
authors.lastname: Kim
authors.forename: Yun Sang
authors.initials: YS
authors.lastname: Lee
authors.forename: Hyung Wook
authors.initials: HW
authors.lastname: Park
authors.forename: Ju Han
authors.initials: JH
authors.lastname: Kim
authors.forename: Young Keun
authors.initials: YK
authors.lastname: Ahn
authors.forename: Jeong Gwan
authors.initials: JG
authors.lastname: Cho
authors.forename: Jong Chun
authors.initials: JC
authors.lastname: Park
authors.forename: Jung Chaee
authors.initials: JC
authors.lastname: Kang
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D002097:C-Reactive Protein / Q000378:metabolism; D017023:Coronary Angiography; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000503:physiopathology; D011379:Prognosis; D011446:Prospective Studies; D019821:Simvastatin / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology
chemical_list: D000960:Hypolipidemic Agents; D005340:Fibrinogen; D002097:C-Reactive Protein; D019821:Simvastatin